Keyphrases
Multiple Myeloma
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
82%
Acute Myeloid Leukemia
43%
Granulocyte Colony-stimulating Factor (G-CSF)
35%
Graft-versus-host Disease (GvHD)
30%
Overall Survival
26%
Hematopoietic Cell Transplantation
25%
Relapsed or Refractory multiple Myeloma
21%
Lenalidomide
21%
Myelodysplastic Syndrome
20%
Complete Remission
19%
Chemotherapy
18%
High Dose
18%
Phase II Study
18%
Plerixafor
18%
Non-Hodgkin Lymphoma
17%
High-dose Therapy
16%
High-dose Chemotherapy
16%
Hematological Malignancies
16%
Transplantation
15%
NCCN Guidelines
15%
Cyclophosphamide
15%
Etoposide
15%
Bortezomib
15%
Leukemia
14%
Peripheral Blood Progenitor Cells
14%
Confidence Interval
14%
Myeloma
14%
Autologous Transplantation
13%
Event-free Survival
13%
Carmustine
13%
High Risk
13%
COVID-19
13%
Pomalidomide
12%
Carfilzomib
12%
Natural Killer Cells
12%
Phase II Trial
12%
CD34+ Cells
12%
Overall Response Rate
12%
Hematopoietic Stem Cells
11%
Engraftment
11%
CD34+
11%
Relapsed or Refractory
11%
Metastatic Breast Cancer
10%
Melphalan
10%
Allogeneic Transplantation
10%
Leukemia Patients
10%
Phase I Study
10%
Relapsed or Refractory Acute Myeloid Leukemia
10%
Cytarabine
10%
Medicine and Dentistry
Multiple Myeloma
91%
Hematopoietic Cell
59%
Cell Transplantation
48%
Acute Myeloid Leukemia
33%
Drug Megadose
26%
Overall Survival
22%
Diseases
21%
COVID-19
19%
Malignant Neoplasm
19%
Oncology
17%
Dexamethasone
17%
Lenalidomide
15%
Myeloma
14%
Granulocyte Colony Stimulating Factor
14%
Carfilzomib
12%
Bortezomib
11%
Stem Cell Transplant
11%
Graft Versus Host Reaction
11%
Non-Hodgkin Lymphoma
11%
High Dose Chemotherapy
11%
Carmustine
10%
Plerixafor
9%
Leukemia
9%
Hematologic Malignancy
9%
Myelodysplastic Syndrome
9%
Natural Killer Cell
9%
Progression Free Survival
9%
Amyloidosis
8%
Event Free Survival
8%
Metastatic Breast Cancer
8%
Stem Cell
8%
Breast Cancer
8%
Cyclophosphamide
8%
Etoposide
8%
Infection
7%
Stem Cell Therapy
7%
Elotuzumab
7%
Pomalidomide
7%
Azacitidine
7%
Decitabine
7%
Light Chain
7%
Allogeneic Stem Cell Transplantation
6%
Immunoglobulin Idiotype
6%
Comorbidity
6%
Allograft
6%
Clinical Research
6%
Whole Body Radiation
6%
Stem Cell Mobilization
6%
Neoplasm
6%
Melphalan
5%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
71%
Chemotherapy
29%
Diseases
26%
Acute Myeloid Leukemia
25%
Overall Survival
23%
Dexamethasone
20%
Remission
19%
Lenalidomide
18%
Carmustine
16%
Granulocyte Colony Stimulating Factor
16%
Myelodysplastic Syndrome
15%
Graft Versus Host Reaction
15%
Bortezomib
15%
Cyclophosphamide
14%
Malignant Neoplasm
13%
Nonhodgkin Lymphoma
13%
Etoposide
13%
Melphalan
12%
Plerixafor
12%
Progression Free Survival
10%
Cytarabine
10%
Carfilzomib
10%
Azacitidine
9%
High Dose Chemotherapy
8%
Hematologic Malignancy
8%
Prednisone
8%
Myeloma
8%
Event Free Survival
7%
Metastatic Breast Cancer
7%
Pomalidomide
7%
Elotuzumab
7%
Amyloidosis
7%
Decitabine
7%
Bendamustine
7%
Infection
7%
Adverse Event
7%
Neoplasm
6%
Chronic Graft Versus Host Disease
6%
Clinical Research
6%
Breast Cancer
5%
Acute Graft Versus Host Disease
5%